CJEU rules out SPCs for new drug formulations, but leaves uncertainty over therapeutic uses

CJEU rules out SPCs for new drug formulations, but leaves uncertainty over therapeutic uses

Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.

Unlock unlimited access to all IAM content